Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.